MIRUM PHARMACEUTICALS INC
MIRMNASDAQ🏆 #1181 by market capUS Equity
$87.46▲ $1.68 (+1.96%)
Latest quoteTrack MIRM
Get earnings, price moves & breaking news on Telegram
24h▲ 2.0%
7d▲ 5.4%
14d▲ 6.3%
30d▼ 0.2%
ytd▲ 10.8%
1y▲ 24.2%
🏦Market Cap
$5.68B
Small Cap
📈Revenue Growth (YoY)
44.0%
High Growth
📊Gross Margin
81.7%
High
💵FCF Margin
9.2%
Moderate
⚖️P/S Ratio
8.9x
Elevated
Otter Score
68
Fair
Trading Snapshot
- Day Range
- $87.12 – $88.39
- 52-Week Range
- $63.23 – $130.00
- Volume (shares)
- 8,914
- Avg Volume (shares)
- —
- Shares Outstanding
- 64.9M
- Next Earnings
- —
Fundamentals Snapshot
- Annual Revenue
- $521M
- Last Q Revenue
- $176M
- P/E Ratio
- —
- P/S Ratio
- 8.9x
- EPS (TTM)
- $-14.55
- Dividend Yield
- —
- Dilution (1yr)
- +3.8%
MIRUM PHARMACEUTICALS INC
MIRMFinancial Trends
RevenueThe total money the company brought in from sales, before subtracting any costs.
$521M▲ +54.7% YoY
Gross MarginOf every $1 of sales, how much is left after the direct cost of making the product/service. Higher = more efficient.
80.7%▲ +6.5% YoY
Operating IncomeProfit from the core business after operating costs, but before interest and taxes. Negative means the core business isn’t profitable yet.
−$22M▼ −74.7% YoY
Free Cash FlowCash left over after running the business and paying for equipment/capex. Negative means the company is burning cash.
$55M▲ +488.0% YoY
Shares OutstandingHow many shares exist. Rising means the company is issuing more shares, which dilutes (shrinks) each existing owner’s slice.
50.2M▲ +3.8% YoY
Net CashCash minus total debt. Positive = more cash than debt (financially strong); negative = more debt than cash (net debt).
−$23M▲ +$72M YoY
StockOtter · stockotter.spaceAbout MIRUM PHARMACEUTICALS INC
Mirum Pharmaceuticals, Inc. is a biopharmaceutical firm dedicated to discovering and commercializing groundbreaking therapies for serious rare and orphan conditions. Its lead experimental drug, LIVMARLI, an oral treatment, is currently undergoing trials for progressive familial intrahepatic cholestasis (PFIC), Alagille syndrome, and biliary atresia. Furthermore, the company is advancing Volixibat to address intrahepatic cholestasis of pregnancy and primary sclerosing cholangitis. Founded in 2018, Mirum Pharmaceuticals, Inc. operates from its headquarters in Foster City, California.
🦦
Otter Score Breakdown
How it's scoredFive components, each rated 1–5★ and equally weighted (20%), averaged to a 0–100 score:💎 Quality — gross margin🚀 Growth — revenue YoY⚖️ Valuation — P/S ratio⚡ Momentum — 30-day price change💧 Dilution — 1-yr share issuance (buybacks score higher)💎Quality★★★★★
🚀Growth★★★★★
⚖️Valuation★★★★★
⚡Momentum★★★★★
💧Dilution★★★★★
Overall Score
Fair
68/100
Analyst data unavailable.
Latest News & Updates
News unavailable.